Tamoxifen metabolism predicts drug concentrations and outcome in premenopausal patients with early breast cancer

Tamoxifen is the standard-of-care treatment for estrogen receptor-positive premenopausal breast cancer. We examined tamoxifen metabolism via blood metabolite concentrations and germline variations of CYP3A5, CYP2C9, CYP2C19 and CYP2D6 in 587 premenopausal patients (Asians, Middle Eastern Arabs, Cauc...

Descripción completa

Detalles Bibliográficos
Autores principales: Saladores, P, Mürdter, T, Eccles, D, Chowbay, B, Zgheib, N K, Winter, S, Ganchev, B, Eccles, B, Gerty, S, Tfayli, A, Lim, J S L, Yap, Y S, Ng, R C H, Wong, N S, Dent, R, Habbal, M Z, Schaeffeler, E, Eichelbaum, M, Schroth, W, Schwab, M, Brauch, H
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2015
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4308646/
https://www.ncbi.nlm.nih.gov/pubmed/25091503
http://dx.doi.org/10.1038/tpj.2014.34

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4308646/
https://www.ncbi.nlm.nih.gov/pubmed/25091503
http://dx.doi.org/10.1038/tpj.2014.34

Ejemplares similares